$SLNO
SOLENO THERAPEUTICS INC

2020 Q3 Form 10-Q Financial Statement

#000156459020052951 Filed on November 10, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q4 2019 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.260M $1.610M $1.620M
YoY Change 39.51% 17.52% 3.85%
% of Gross Profit
Research & Development $4.830M $5.270M $4.490M
YoY Change 7.57% 140.64% 114.63%
% of Gross Profit
Depreciation & Amortization $490.0K $490.0K $490.0K
YoY Change 0.0% 0.0% 0.0%
% of Gross Profit
Operating Expenses $7.090M $6.880M $6.133M
YoY Change 15.6% 93.26% 58.15%
Operating Profit -$6.133M
YoY Change 58.15%
Interest Expense $0.00 -$120.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net -$688.0K -$7.870M $7.022M
YoY Change -109.8% -507.77% 347.55%
Pretax Income -$8.550M -$14.63M $890.0K
YoY Change -1060.67% -3851.28% -138.53%
Income Tax
% Of Pretax Income
Net Earnings -$8.550M -$14.63M $889.0K
YoY Change -1061.75% -5726.92% -132.49%
Net Earnings / Revenue
Basic Earnings Per Share -$0.11 $0.03
Diluted Earnings Per Share -$0.11 -$354.8K -$0.19
COMMON SHARES
Basic Shares Outstanding 44.66M 31.79M
Diluted Shares Outstanding 79.58M 32.44M

Balance Sheet

Concept 2020 Q3 2019 Q4 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $56.14M $20.73M $11.23M
YoY Change 399.91% -13.91% 9.67%
Cash & Equivalents $56.14M $20.73M $11.23M
Short-Term Investments $0.00
Other Short-Term Assets $350.0K $410.0K $380.0K
YoY Change -7.89% -22.64% -67.8%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $56.49M $21.14M $11.61M
YoY Change 386.61% -14.29% 1.72%
LONG-TERM ASSETS
Property, Plant & Equipment $230.0K $22.00K $46.00K
YoY Change 400.0% 83.33% 228.57%
Goodwill
YoY Change
Intangibles $15.07M $16.53M $17.01M
YoY Change -11.43% -10.53% -10.26%
Long-Term Investments
YoY Change
Other Assets $59.00K $59.00K
YoY Change -86.89%
Total Long-Term Assets $15.29M $17.03M $17.12M
YoY Change -10.65% -7.86% -11.87%
TOTAL ASSETS
Total Short-Term Assets $56.49M $21.14M $11.61M
Total Long-Term Assets $15.29M $17.03M $17.12M
Total Assets $71.78M $38.17M $28.73M
YoY Change 149.9% -11.54% -6.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.213M $1.995M $1.735M
YoY Change 85.19% 113.6% 39.36%
Accrued Expenses $4.380M $2.590M $1.720M
YoY Change 154.65% 175.53% 49.57%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.996M $4.964M $3.454M
YoY Change 131.5% 164.46% 37.72%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $15.78M $147.0K $38.00K
YoY Change 41426.32% -98.65% -99.73%
Total Long-Term Liabilities $15.78M $147.0K $38.00K
YoY Change 41426.32% -98.65% -99.73%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.996M $4.964M $3.454M
Total Long-Term Liabilities $15.78M $147.0K $38.00K
Total Liabilities $23.78M $23.23M $13.84M
YoY Change 71.82% 82.33% -16.78%
SHAREHOLDERS EQUITY
Retained Earnings -$179.6M -$157.8M -$143.2M
YoY Change 25.43% 24.23% 12.48%
Common Stock $227.6M $172.8M $158.1M
YoY Change 43.99% 9.72% 11.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $48.01M $14.95M $14.89M
YoY Change
Total Liabilities & Shareholders Equity $71.78M $38.17M $28.73M
YoY Change 149.9% -11.54% -6.84%

Cashflow Statement

Concept 2020 Q3 2019 Q4 2019 Q3
OPERATING ACTIVITIES
Net Income -$8.550M -$14.63M $889.0K
YoY Change -1061.75% -5726.92% -132.49%
Depreciation, Depletion And Amortization $490.0K $490.0K $490.0K
YoY Change 0.0% 0.0% 0.0%
Cash From Operating Activities -$6.170M -$5.080M -$4.720M
YoY Change 30.72% 36.19% 76.12%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $110.0K $440.0K
YoY Change -164.71%
Cash From Investing Activities $0.00 $100.0K $450.0K
YoY Change -100.0% -158.82% -4600.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -200.0K 14.48M 0.000
YoY Change -11.17% -100.0%
NET CHANGE
Cash From Operating Activities -6.170M -5.080M -4.720M
Cash From Investing Activities 0.000 100.0K 450.0K
Cash From Financing Activities -200.0K 14.48M 0.000
Net Change In Cash -6.370M 9.500M -4.270M
YoY Change 49.18% -23.39% 114.57%
FREE CASH FLOW
Cash From Operating Activities -$6.170M -$5.080M -$4.720M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$6.170M -$5.080M -$4.720M
YoY Change 30.72% 36.19% 76.78%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
147000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
48006000
CY2019Q4 us-gaap Liabilities
Liabilities
23225000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
80000
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
227519000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-179593000
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
16525000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
220000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17625000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
59000
CY2020Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
17000
CY2019Q4 us-gaap Assets
Assets
38172000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1995000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
283000
CY2019Q4 slno Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
1999000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
305000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
382000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4964000
CY2019Q4 slno Asset Acquisition Contingent Consideration Liability Noncurrent
AssetAcquisitionContingentConsiderationLiabilityNoncurrent
5938000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4490000
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
71784000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44658054
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31793292
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56916137
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31775590
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79583254
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
392000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-5858000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
9481000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
341000
CY2020Q2 slno Issuance Of Common Stock Value Under Equity Incentive Plans
IssuanceOfCommonStockValueUnderEquityIncentivePlans
17000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-7030000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
23631000
CY2020Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
15067000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1615000
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
220000
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
408000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
7996000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
756000
CY2020Q3 slno Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
3399000
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3213000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
79593621
CY2020Q3 us-gaap Assets
Assets
71784000
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
79593621
us-gaap Operating Lease Cost
OperatingLeaseCost
229000
CY2019Q3 slno Operating Lease Cost And Sublease Income
OperatingLeaseCostAndSubleaseIncome
65000
slno Operating Lease Cost And Sublease Income
OperatingLeaseCostAndSubleaseIncome
229000
CY2020Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
2000
CY2019Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
24000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
374000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-7384000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
56177000
us-gaap Operating Expenses
OperatingExpenses
16734000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6133000
us-gaap Operating Income Loss
OperatingIncomeLoss
-28332000
us-gaap Operating Income Loss
OperatingIncomeLoss
-16734000
CY2019Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-7116000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6532000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-930000
CY2019Q3 slno Income Loss From Minority Interest Investments
IncomeLossFromMinorityInterestInvestments
-123000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44658054
slno Asset Acquisition Contingent Consideration Change In Fair Value
AssetAcquisitionContingentConsiderationChangeInFairValue
4200000
slno Asset Acquisition Contingent Consideration Change In Fair Value
AssetAcquisitionContingentConsiderationChangeInFairValue
417000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
6133000
us-gaap Operating Expenses
OperatingExpenses
28332000
slno Income Loss From Minority Interest Investments
IncomeLossFromMinorityInterestInvestments
-478000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
29000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
133000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-688000
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7022000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6545000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
585000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
889000
us-gaap Net Income Loss
NetIncomeLoss
-21787000
us-gaap Net Income Loss
NetIncomeLoss
-16149000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:inherit;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of expenses in the financial statements and accompanying notes. Actual results could differ from those estimates. Key estimates included in the financial statements include the valuation of deferred income tax assets, the valuation of financial instruments, stock-based compensation, value and life of acquired intangibles, and the valuation of contingent liabilities. The contingent liability represents the fair value of the contingent consideration arising from the Company&#8217;s acquisition of Essentialis in 2017. As part of the purchase price, the Company is obligated to make cash earn out payments to Essentialis stockholders up to a maximum of $30 million upon the achievement of certain commercial milestones.</font></p>
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-10008000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
13843000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
14885000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3778000
us-gaap Profit Loss
ProfitLoss
-21787000
us-gaap Profit Loss
ProfitLoss
-16149000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1466000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1468000
slno Noncash Lease Expense
NoncashLeaseExpense
210000
slno Noncash Lease Expense
NoncashLeaseExpense
322000
us-gaap Share Based Compensation
ShareBasedCompensation
1107000
us-gaap Share Based Compensation
ShareBasedCompensation
621000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-478000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-154000
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
-55000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
801000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
4000
slno Increase Decrease In Accrued Clinical Trial Site Costs
IncreaseDecreaseInAccruedClinicalTrialSiteCosts
711000
slno Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-318000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
67000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12299000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
16000
slno Payments To Security Deposit On Sublease
PaymentsToSecurityDepositOnSublease
59000
slno Proceeds From Sale Of Minority Interest Investment In Former Subsidiary
ProceedsFromSaleOfMinorityInterestInvestmentInFormerSubsidiary
500000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
425000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
53760000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
17000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
13000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
53764000
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
28000
slno Financing Costs In Accounts Payable And Accrued Liabilities
FinancingCostsInAccountsPayableAndAccruedLiabilities
38000
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
76000
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
108000
us-gaap Operating Lease Cost
OperatingLeaseCost
340000
CY2019Q3 us-gaap Sublease Income
SubleaseIncome
43000
us-gaap Sublease Income
SubleaseIncome
173000
CY2020Q3 slno Operating Lease Cost And Sublease Income
OperatingLeaseCostAndSubleaseIncome
76000
slno Operating Lease Cost And Sublease Income
OperatingLeaseCostAndSubleaseIncome
167000
CY2019Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
1000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
7000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
1000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1000
slno Incremental Common Shares Attributable To Options To Purchase Common Stock
IncrementalCommonSharesAttributableToOptionsToPurchaseCommonStock
236395
CY2019Q3 slno Incremental Common Shares Attributable To Warrants
IncrementalCommonSharesAttributableToWarrants
389473
slno Incremental Common Shares Attributable To Warrants
IncrementalCommonSharesAttributableToWarrants
223543
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10291891
CY2020Q3 slno Finance Lease Cost
FinanceLeaseCost
2000
CY2019Q3 slno Finance Lease Cost
FinanceLeaseCost
1000
slno Finance Lease Cost
FinanceLeaseCost
8000
slno Finance Lease Cost
FinanceLeaseCost
1000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
374000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
153000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1107000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
621000
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.004
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.84
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.89
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.17
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1000000
CY2019Q3 us-gaap Dilutive Securities
DilutiveSecurities
-7090000
us-gaap Dilutive Securities
DilutiveSecurities
-906000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-8545000
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6201000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-21787000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-17055000
CY2019Q3 slno Incremental Common Shares Attributable To Options To Purchase Common Stock
IncrementalCommonSharesAttributableToOptionsToPurchaseCommonStock
260882
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9286325
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10291891
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9476743
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000

Files In Submission

Name View Source Status
0001564590-20-052951-index-headers.html Edgar Link pending
0001564590-20-052951-index.html Edgar Link pending
0001564590-20-052951.txt Edgar Link pending
0001564590-20-052951-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
slno-10q_20200930.htm Edgar Link pending
slno-20200930.xml Edgar Link completed
slno-20200930.xsd Edgar Link pending
slno-20200930_cal.xml Edgar Link unprocessable
slno-20200930_def.xml Edgar Link unprocessable
slno-20200930_lab.xml Edgar Link unprocessable
slno-20200930_pre.xml Edgar Link unprocessable
slno-ex311_8.htm Edgar Link pending
slno-ex312_7.htm Edgar Link pending
slno-ex321_9.htm Edgar Link pending
slno-ex322_6.htm Edgar Link pending